The stock of CareDx Inc (NASDAQ:CDNA) is a huge mover today! About 146,007 shares traded hands or 862.28% up from the average. CareDx Inc (NASDAQ:CDNA) has declined 31.19% since April 20, 2016 and is downtrending. It has underperformed by 35.75% the S&P500.
The move comes after 6 months positive chart setup for the $77.70M company. It was reported on Nov, 22 by Barchart.com. We have $4.06 PT which if reached, will make NASDAQ:CDNA worth $4.66M more.
CareDx Inc (NASDAQ:CDNA) Ratings Coverage
Out of 3 analysts covering CareDx (NASDAQ:CDNA), 2 rate it a “Buy”, 0 “Sell”, while 1 “Hold”. This means 67% are positive. CareDx has been the topic of 4 analyst reports since September 25, 2015 according to StockzIntelligence Inc. Craig Hallum initiated the stock with “Buy” rating in Friday, September 25 report. The rating was downgraded by Raymond James on Monday, September 28 to “Market Perform”. As per Tuesday, June 14, the company rating was maintained by Mizuho.
According to Zacks Investment Research, “CareDx, Inc. is a commercial stage company. It develops, markets, and delivers a diagnostic surveillance solution for heart transplant recipients. The Company provides AlloMap, a noninvasive blood test used to aid in the identification of heart transplant recipients. It is also pursuing other areas of transplant surveillance, such as the use of cell-free DNA (cfDNA) as a biomarker for rejection. CareDx, Inc. is based in Brisbane, California.”
Insitutional Activity: The institutional sentiment increased to 1.71 in 2016 Q2. Its up 0.14, from 1.57 in 2016Q1. The ratio improved, as 1 funds sold all CareDx Inc shares owned while 6 reduced positions. 4 funds bought stakes while 7 increased positions. They now own 5.81 million shares or 18.74% more from 4.90 million shares in 2016Q1.
Blackrock Institutional Na holds 0% or 5,838 shares in its portfolio. Blackrock Invest Llc holds 0% or 1,496 shares in its portfolio. Tpg Group (Sbs) Advisors has 0.05% invested in the company for 1.08M shares. Gagnon Securities Ltd Co last reported 2.76% of its portfolio in the stock. Geode Cap Mgmt Lc has 15,112 shares for 0% of their US portfolio. Thompson Davis holds 0.01% of its portfolio in CareDx Inc (NASDAQ:CDNA) for 2,000 shares. Gabelli Funds Lc has invested 0% of its portfolio in CareDx Inc (NASDAQ:CDNA). Comml Bank Of America De reported 201 shares or 0% of all its holdings. Blackrock Fund Advisors holds 21,535 shares or 0% of its portfolio. The California-based California Employees Retirement System has invested 0% in CareDx Inc (NASDAQ:CDNA). Goldman Sachs Gp reported 54,141 shares or 0% of all its holdings. Spark Invest Management Ltd Company holds 0.01% of its portfolio in CareDx Inc (NASDAQ:CDNA) for 16,400 shares. Gagnon Ltd Liability last reported 952,464 shares in the company. Paragon Associates And Paragon Associates Ii Joint Venture has invested 4.95% of its portfolio in CareDx Inc (NASDAQ:CDNA). Teton Advsrs holds 10,000 shares or 0% of its portfolio.
Insider Transactions: Since September 21, 2016, the stock had 3 insider purchases, and 0 sales for $794,511 net activity. Nelles Mitchell J had bought 10,000 shares worth $40,000. GAGNON NEIL had bought 178,686 shares worth $714,511 on Wednesday, September 21. 10,000 shares were bought by Whitson Todd, worth $40,000 on Monday, September 26.
CDNA Company Profile
CareDx, Inc., incorporated on December 21, 1998, is a molecular diagnostics company. The Firm is focused on the discovery, development and commercialization of clinically differentiated diagnostic surveillance solutions for transplant patients. The Company’s commercialized testing solution, the AlloMap heart transplant molecular test (AlloMap) is a gene expression test that helps clinicians monitor and identify heart transplant recipients with stable graft function having a low probability of moderate/severe acute cellular rejection. AlloMap is a non-invasive method recommended in the International Society for Heart and Lung Transplantation (ISHLT) patient care guidelines for surveillance of heart transplant rejection in patients 15 years of age or older.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.